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Abstract
Background: Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries.
The polymorphism rs10490924 in the ARMS2 gene is highly associated with AMD and linked to an indel mutation
(del443ins54), the latter inducing mRNA instability. At present, the function of the ARMS2 protein, the exact cellular
sources in the retina and the biological consequences of the rs10490924 polymorphism are unclear.
Methods: Recombinant ARMS2 was expressed in Pichia pastoris, and protein functions were studied regarding cell
surface binding and complement activation in human serum using fluoresence-activated cell sorting (FACS) as well
as laser scanning microscopy (LSM). Biolayer interferometry defined protein interactions. Furthermore, endogenous
ARMS2 gene expression was studied in human blood derived monocytes and in human induced pluripotent stem
cell-derived microglia (iPSdM) by PCR and LSM. The ARMS2 protein was localized in human genotyped retinal
sections and in purified monocytes derived from AMD patients without the ARMS2 risk variant by LSM. ARMS2
expression in monocytes under oxidative stress was determined by Western blot analysis.
Results: Here, we demonstrate for the first time that ARMS2 functions as surface complement regulator. Recombinant
ARMS2 binds to human apoptotic and necrotic cells and initiates complement activation by recruiting the complement
activator properdin. ARMS2-properdin complexes augment C3b surface opsonization for phagocytosis. We also
demonstrate for the first time expression of ARMS2 in human monocytes especially under oxidative stress and in
microglia cells of the human retina. The ARMS2 protein is absent in monocytes and also in microglia cells,
derived from patients homozygous for the ARMS2 AMD risk variant (rs10490924).
Conclusions: ARMS2 is likely involved in complement-mediated clearance of cellular debris. As AMD patients
present with accumulated proteins and lipids on Bruch’s membrane, ARMS2 protein deficiency due to the
genetic risk variant might be involved in drusen formation.
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Background
Age-related macular degeneration (AMD) is a multi-
factorial disease and a prevalent cause of visual impairment
in developed countries [1]. Genome-wide association stud-
ies revealed that variations in or near the complement
genes CFH [2–5], CFI [6], CFB [7], and C3 [8] are sig-
nificantly associated with AMD. Thus, inappropriate
complement activation and innate immunity are linked
to the pathogenesis of AMD [1]. The complement sys-
tem is a major part of innate immunity and plays an es-
sential role in cellular homeostasis, tissue remodeling, as
well as in host defense and inflammation [9, 10]. Deregu-
lated complement function or uncontrolled activation due
to defective regulation has been implicated in AMD and
other diseases including C3-glomerulopathy, paroxysmal
nocturnal hemoglobinuria, and systemic lupus erythema-
tosus [9–11].
In addition to mutations in complement genes, a poly-
morphism (rs10490924) in ARMS2 shows the highest as-
sociation with AMD with an estimated relative risk of 8.1
for homozygous carriers [12–14]. The ARMS2 gene is
present only in higher primates [15], and cellular expres-
sion and function of ARMS2 are widely unknown. Here,
we focused on the role of ARMS2 in AMD pathophysi-
ology and aimed at defining the functional consequences
of the AMD associated polymorphism (rs10490924) in
ARMS2. Our findings demonstrate ARMS2 expression in
human monocytes and microglia cells and suggest that
ARMS2 functions are directly linked to the complement




The polymorphism in the ARMS2 gene, rs10490924
was described as highly associated with both forms of
AMD leading to geographic atrophy (dry form) or
neo-vascularization (wet form) [12, 13]. Patients diag-
nosed with the wet form of AMD according to the modi-
fied version of AMD study grading system (AREDS) as
described previously by Spencer et al. [16] were genotyped
for the polymorphisms in the ARMS2 gene rs2736911,
rs10490924, and del443ins54 as described [2, 12]. Gen-
omic DNA was extracted from 10 ml whole blood cells of
each patient using the PAX gene blood DNA kit (QiaGen).
ARMS2 was amplified with primers (forward 5′TGTCAC-
CACATTATGTCCC3′ or 5′TGTCACTGCATTCCC
TCCTGTCAT3′ and reverse 5′GGCACCACTCCAGA
ATTT3′ or 5′AAGCTTCTTACCCTGACTTCCAGC3′),
and the PCR products were separated by agarose gel elec-
trophoresis, visualized under UV light and subsequently
validated by bi-directional sequencing on an automated
DNA sequencer (ABI/1130x, Applied Biosystems). Ac-
cording to the presence of the polymorphisms rs2736911,
rs10490924, and del443ins54 in the ARMS2 gene, three
groups of genotypes were created (homozygous without
these polymorphisms (type I/I), heterozygous for rs1049
0924 and del443ins54 (type I/II), homozygous for rs1049
0924 and del443ins54 (type II/II), and homozygous for
rs2736911 (type III/III).
Human donor eyes
Retinal samples of controls and AMD patients were ob-
tained from the Center of Ophthalmology Eye Bank,
University of Cologne. Retina 1: type I/I, craniocerebral
injury, unknown hour postmortem, age 22. Retina 2:
type I/I, intracranial bleeding, 27 h postmortem, age 82.
Retina 3: type I/I, hypoxia brain damage, 4.5 h postmor-
tem, age 53. Retina 4: type II/II, exenteratio orbitae, 8 h
postmortem, age 78.
Cells
CHO-K1 Chinese ovary hamster cells (ATCC-CCL-61),
pgsD-677 heparan sulfate deficient CHO cells (ATCC CRL-
2244), pgsA-745 xylosyltransferase 1 deficient CHO cells
(ATCC CRL-2242), THP-1 human monocytes (ATCC TIB-
202), RAW264.7 Mouse leukemic macrophages (ATCC
TIB-71), and native RPE cells (InnoProt) were all cultivated
according to the costumer’s advise. Human T cells, mono-
cytes, and human erythrocytes were obtained from human
blood samples of healthy volunteers. Human T cells, per-
ipheral blood mononuclear cells (PBMCs), and erythrocytes
were isolated with micro beads from Miltenyi Biotech, ac-
cording to the manufacturer’s protocol. Apoptosis of cells
was induced by incubation of the cells with 0.4 μg/ml staur-
osporine for 24 h and necrosis by 1 h at 65 °C. Apoptosis
was confirmed by PI and annexin V-pacific blue positive
staining (Life Technologies) using flow cytometry. Human
microglia cell lines (iPSdM) were generated from induced
pluripotent stem (iPS) cell lines obtained by reprogram-
ming skin fibroblasts as previously described [17]. The cells
proliferate without addition of growth factors, and they
were passaged 1:3 twice a week. The microglia phenotype
was confirmed by flow cytometry by expression of CD11b,
CD11c, CD14, CD16, CD32, CD36, CD45, CD206,
CX3CR1, and TREM2.
ARMS2 gene expression (PCR)
Cells (about 1 × 106 from each cell type) with or without
stimulation by 400 ng PMA LPS for 24 h or of 10 ml
whole blood were harvested and homogenized; total RNA
was isolated using the PAX gene blood RNA kit (QiaGen).
A 20 ng of isolated RNA was transcribed into cDNA using
QuantiTect® Reverse Transcription Kit (QiaGen). cDNA
was amplified using Phusion PCR Kit (New England Bio-
labs), and primers situated in exon 1 (5′TCGGTGGTTCC
TGTGTCCTTCATT3′) and exon 2 (5′TCACCTTGCTG
CAGTGTGGATGAT3′) of ARMS2 or for amplification
Micklisch et al. Journal of Neuroinflammation  (2017) 14:4 Page 2 of 15
of actin (forward 5′ACCAACTGGGACGACAT3′; re-
verse 5′CTAGAAGCATTTGCGGTG3′). Synthesis was
performed by denaturing for 60 s at 96 °C followed by an-
nealing for 30 s at 69 °C (ARMS2) or 60 °C (actin) and
synthesis for 60 s (ARMS2) or 120 s (actin) at 72 °C for 35
cycles. Extension was performed for 480 s at 72 °C. Ampli-
fied PCR products were separated in agarose and visual-
ized under UV light. Bands were excised, purified, and
sequenced on an automated DNA sequencer (ABI/1130x,
Applied Biosystems). Sequences were aligned to ARMS2
genomic sequences (NM_001099667).
Expression and purification of recombinant ARMS2
ARMS2 was recombinant expressed using the Pichia pas-
toris expression system. The expression vector pPICZB
contained codon usage optimized full length cDNA of the
ARMS2 gene coupled to a myc and 6 × histidine coding
tag for purification (Life Technologies) (Additional file 1:
Figure S1). P. pastoris cells (strain X33) were transformed
with the recombinant expression vector, and ARMS2
expressing clones were selected via zeocin containing se-
lection medium according to the standard protocols.
Expressed His-tagged proteins were purified by Ni2+-che-
late affinity chromatography from the cells [18, 19]. Cell
lyses were performed in binding buffer (10 mM Na2HPO4,
10 mM NaH2PO4, 10 mM imidazol, 1 M NaCl, 2% (v/v)
Nonidet P-40, 20% (v/v) glycerol; pH 7.0) together with
glass beads (Roth) by FastPrep®-24 (MP Biomedicals) at
4 m/s for 60 s. Protease activity was inhibited by addition
of complete EDTA-free (Roche). Protein was eluted from
HisTrap™ HP column (GE Healthcare) using elution buffer
(10 mM Na2HPO4, 10 mM NaH2PO4, 500 mM imidazol,
500 mM NaCl; pH 7.0). Purified ARMS2 was concen-
trated in storage buffer (10 mM Na2HPO4, 10 mM
NaH2PO4, 500 mM NaCl; pH 7.0). In addition to the re-
combinant protein, three ARMS2 peptides were gener-
ated. Peptide 1 included amino acids 1 to 40, peptide 2
amino acids 41 to 70, and peptide 3 amino acids 71 to 107
(Jerini Peptide Biotechnologies). Polyclonal ARMS2 anti-
serum was generated by immunization of rabbits with the
here described recombinant ARMS2 protein expressed in
P. pastoris (Davids Biotechnologies). Generated ARMS2
antiserum (ARMS2Jena) was purified with HiTrap Protein A
HP 1 ml column (GE Healthcare) and the major epitope of
these antibodies determined by pepspot analysis. Peptides
of ARMS2 (33 peptides of 13 amino acids with three amino
acids overlap) were spotted to a membrane (Jerini Peptide
Technologies), incubated with the antiserum and secondary
anti-rabbit antibodies for detection. Polyclonal rabbit
antiserum generated to the N-terminus of ARMS2
(ARMS2com) was purchased from CovaLab. In
addition, a mouse monoclonal antibody was generated
to the C-terminal peptide 3 of ARMS2 (aa 71–107 =
IHTELCLPAFFSPAGTQRRFQQPQHHLTLSIIHTAAR)
(ARMS2mAb) by standard methods.
Recombinant ARMS2 was separated by SDS-PAGE
under reducing conditions (50 mM TRIS-HCL, 1.6% (w/v)
SDS, 7% (v/v) glycerol, 8 M UREA, 4% (v/v) β-
mercaptoethanol, 0.016% (w/v) bromophenol blue; pH 6.8)
and visualized either by silver staining or immune-blotting
using ARMS2com, ARMS2Jena antiserum, or mouse α-
Penta-His monoclonal antibodies (QiaGen). Mass of whole
deglycosylated recombinant ARMS2 was determined by
mass spectrometry. To remove the carbohydrate side
chains from recombinant ARMS2 (10 μg), the protein was
incubated with 0.5 units of PNGase (Roche) for 3 h at 37 °
C or the purification tag was cleaved off by enterokinase
(New England Biolabs) overnight at RT and repurified with
a HisTrap™ HP column.
For immunoprecipitation, monoclonal α-ARMS2 anti-
body (20 μg) was loaded onto Protein G Magnetic beads
(New England BioLabs) for 1 h at 4 °C in binding buffer
(20 mM sodium phosphate buffer, pH 7.0). THP-1 cells
(1 × 107) were lysed in 1 ml lysis buffer (150 mM NaCl,
1% NP-40, 25 nM Tris-HCl, 1 mM EDTA, 5% glycerol)
containing 1 mM PMSF, centrifuged at 16,000 g for
10 min at 4 °C, added to the antibody-loaded beads and
incubated on a rotating shaker overnight at 4 °C. After re-
moval of the supernatant, the beads were washed and pro-
teins were eluted from the beads in 30 μl of elution buffer
(0.1 M glycine, pH 2.7). The eluted proteins were evalu-
ated for the presence of ARMS2 by SDS-PAGE and mass
spectrometry. To show endogenous ARMS2 expression,
monocytes were isolated from fresh blood and about 1 ×
106 cells were stressed by addition of H2O2 (0.001–1 mM)
for 1 h. Supernatants were replaced by cell culture
medium, and cells were incubated for 20 h. Cells were
lysed in buffer (50 mM TRIS-HCL, 1.6% (w/v) SDS, 7%
(v/v) glycerol, 8 M UREA, 4% (v/v) β-mercaptoethanol,
0.016% (w/v) bromophenol blue; pH 6.8), centrifuged and
supernatants were separated by SDS PAGE, blotted to a
membrane and ARMS2 detected with αARMS2Jena.
Mass spectrometry
Recombinant ARMS2 or immunoprecipitated ARMS2
from THP-1 cells were separated by SDS-PAGE and
stained with coomassie blue. Protein bands were excised
from the gel and washed repeatedly in water and 50 mM
NH4HCO3/acetonitrile 1 + 1 (v/v) for 15 min. Gel pieces in
acetonitrile were dried by vacuum centrifugation. Gel
pieces were soaked in 50 mM NH4HCO3 with 10 mM
DTT for 45 min at 56 °C followed by alkylation (50 mM
iodoacetamide in 50 mM NH4HCO3 for 30 min in the
dark). Upon washing in 50 mM NH4HCO3/acetonitrile, gel
pieces were incubated in trypsin digestion buffer (20 ng/μl
trypsin in 25 mM NH4HCO3) overnight at 37 °C. The pep-
tides were extracted from the gel plugs by incubation in
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acetonitrile/trifluoroacetic acid 1 + 1 (v/v) for 30 min at RT.
Extracted peptides (1 μl) were premixed with the same vol-
ume of the matrix α-CHCA solution and spotted on a
matrix-assisted laser desorption ionization (MALDI) plate.
Mass was analyzed using MALDI TOF-mass spectrometer
(UltrafleXtreme, Bruker Daltonics, Germany) in the re-
flector mode with appropriatem/z range and laser intensity.
For analysis of the whole ARMS2 protein, the recombinant
protein was deglycosylated and untagged as described
above. Analysis of the protein, the instrument was utilized
in linear mode. Data analysis was performed with current
NCBInr database using Mascot search with a peptide mass
tolerance of 100 ppm. The analysis was repeated three
times.
Detection of endogenous ARMS2 by LSM microscopy
For detection of endogenous ARMS2 protein, monocytes
of seven ARMS2 genotyped individuals (two (I/I), one (I/
II), two (II/II) one (III/III)) were isolated from PBMCs de-
rived from 20 to 40 ml human blood samples. Blood sam-
ples were diluted 1:1 in PBS and overlaid with 15 ml Ficoll.
After centrifugation at 1600 rpm for 20 min, PBMCs were
collected and washed in 10 ml PBS. Monocytes were iso-
lated from PBMCs using a Percoll gradient (3 ml of PBMCs
were overlaid by 6 ml of 54% Percoll) centrifuged as above,
harvested, and washed in ice-cold PBS. Cells (1 × 106) were
transferred into a 4-well slide chamber (Lab-Tek®) and
stained for laser scanning microscopy as previously de-
scribed [19]. Briefly, isolated monocytes or THP-1 cells in
chamber slides were fixed with paraformaldehyde (3% at
RT for 15 min) permeabilized in Triton X-100 (0.3%) (Roth)
5 min on ice, blocked with FcR blocking reagent (Miltenyi)
10 min at 4 °C and stained with polyclonal rabbit ARMS2
antiserum (αARMS2Jena) (1:200), monoclonal ARMS2 anti-
bodies (αARMS2mAb) (1:200) followed by incubation with
Alexa-647 labeled anti-rabbit or anti-mouse (1:400) for 1 h
at RT. DNA was stained with DAPI (10 μg/ml) for 15 min
at RT. After washing, the samples were examined by LSM
(LSM 510, Carl Zeiss, Jena).
CHO-K1 cells (~1 × 105) were incubated with 10 μg
ARMS2 and properdin, either alone or together. After 1 h,
cells were washed and placed on a chamber slide (Nunc).
After 1 h, adherent cells were fixed with 3% paraformalde-
hyde for 15 min. CHO surface-bound ARMS2 was visual-
ized using rabbit ARMS2 antiserum (1:100) and Alexa-488
conjugated secondary antibody (1:200; Life Technologies)
in assay buffer (1% BSA in RPMI media). Properdin was
detected by mouse monoclonal properdin antibody (1:100;
QuiDel) and secondary Alexa-647 conjugated antibody
(1:200; Life Technologies) in assay buffer. DAPI (Sigma)
was used to stain DNA. Images were taken by LSM 710
Meta (Zeiss) and co-localization was analyzed with Zen
2009 software (Zeiss). All incubation steps were done in
RPMI media at RT.
Histology
Eyes were soaked in phosphate buffered saline (PBS) con-
taining 4% formaldehyde followed by punching of a tissue
strip ranging from the optic nerve to the fovea/parafovea
which was then processed for paraffin embedding. Sections
of 12 μm thickness derived from 2 genotyped individuals
(genotype (I/I) and (II/II)) were obtained and subjected to
immunohistochemical staining. After de-paraffinization by
a series of graded ethanol slides were placed in a 97 °C hot
water bath in antigen retrieval buffer (0.05 M Tris buffered
saline, 0.05% Tween-20, pH 9.0) for 20 min. Slides were
then washed with 1% goat serum in 1xPBS-T (PBS with
0.4% Triton-X) for 10 min for two times. To prevent unspe-
cific binding, sections were covered with blocking buffer
(5% goat serum in 1xPBS-T) in a humidified chamber and
incubated for 30 min at room temperature. Primary anti-
bodies included anti-ARMS2 (1:200, rabbit polyclonal),
anti-CD68 (1:200, monoclonal rat anti-mouse, AbDSer-
otec), and anti-CD68 (1:200, monoclonal mouse anti-
human, Dako). Primary antibodies were incubated over-
night at 4 °C. After the two washing steps with 1%
serum PBS-T, sections were incubated with labeled sec-
ondary antibodies coupled to Alexa-488 (green) or Alexa-
594 (red) (Jackson ImmunoResearch, West Grove, PA,
USA). Retinal nuclei were counter-stained with DAPI and
mounted in DAKO fluorescent mounting medium (Dako
Deutschland GmbH, Hamburg, Germany) and analyzed




ARMS2 binding to complement proteins C3, C3b,
C3c, C3d, iC3b, factor B, properdin (all Complement
Technologies) and human serum albumin (HSA) (Nu-
tritional Biochemicals) (each 500 ng in PBS) were
coated onto MediSorp microtiter plates (Nunc) over
night at 4 °C. Wells were blocked with buffer I (Appli-
Chem) for 2 h at RT and incubated with 500 ng ARMS2
in assay buffer (2% (w/v) BSA, 0.05% (v/v) Tween-20 in
PBS) for 1 h at RT. ARMS2 was detected with ARMS2
antiserum diluted 1:1000 and a secondary HRP conju-
gated antibody 1:2000 in CrossDown buffer (Appli-
Chem) at 492 nm.
Properdin binding to ARMS2 Recombinant ARMS2 or
HSA (each 500 ng in PBS) was coated onto MaxiSorp
microtiter plates (Nunc) over night at 4 °C. Wells were
then washed with PBS + 0.05% (v/v) Tween-20 and
blocking was performed with blocking buffer (5% (w/v)
BSA, 0.05% (v/v) Tween-20 in PBS) for 2 h at RT. After
another washing step, wells were incubated with increas-
ing amounts of properdin (12.5–100 nM) in assay buffer
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(2% (w/v) BSA, 0.05% (v/v) Tween-20 in PBS). After in-
cubation for 1 h at RT, wells were washed and bound
properdin was detected with a goat properdin antiserum
diluted 1:2000 and a secondary horse radish peroxidate
(HRP)–conjugated antibody diluted 1:2000 in assay buf-
fer. Multiscan Ascent ELISA Reader measured absorp-
tion at 492 nm. To determine the interaction domain in
ARMS2 responsible for properdin binding to ARMS2,
peptide 1, peptide 2, and peptide 3 (each 500 nM) were
coated to the microtiter plate, incubated with 2 μM pro-
perdin (TECOmedical GmbH) in PBS and binding of
properdin was detected as described before. Primary
monoclonal properdin antibody (1:1000) [20] and sec-
ondary anti mouse 1:2000 (Dako, Denmark) were used
for detection.
The binding affinity of properdin to ARMS2 was mea-
sured using biolayer interferometry on a BLITZ system
(Forte Bio). His-tagged ARMS2 was loaded onto Ni2+
NTA biosensors (Forte Bio) in assay buffer (PBS (Lonza)
with 0.1% (m/v) gelatin). Loaded biosensors were
blocked using assay buffer with 10 μg/ml biocytin
(Sigma-Aldrich) for 60 s. After washing, the biosensors
were dipped in 4-μl properdin solution with concentra-
tions varying from 70 to 1800 nM properdin. The kD
was determined by fitting data to a 1:1 model algorithm
with the BLITZ software.
Recruitment of C3b by ARMS2 bound properdin Pro-
perdin (100 nM) was bound to immobilized recombin-
ant ARMS2 as described before. Wells were washed
with assay buffer (2% (w/v) BSA, 0.05% (v/v) Tween-20
in PBS) and incubated with increasing amounts of C3b
(4–12 nM) in assay buffer for 1 h at RT. Unbound C3b
was removed by additional wash steps, and binding was
detected at 492 nm by mouse C3d monoclonal antibody
(1:2000, Quidel) and secondary HRP-conjugated anti-
body (1:2000) in assay buffer.
Ba activities ARMS2 (500 nM) was incubated with 20%
NHS in Mg2+EGTA buffer (1% (w/v) BSA, 20 mM
HEPES, 144 mM NaCl, 7 mM MgCl2, 10 mM EGTA,
pH 7.4) for 15 min at 37 °C. The generated Ba product
was analyzed at 540 nm using a Ba MicroVUE ELISA
Kit (QuiDel).
Flow cytometry
All fluoresence-activated cell sorting (FACS) analyses
were performed with a LSR II flow cytometer (BD Sci-
ence); 10,000 cells were evaluated and data were calcu-
lated using FlowJo Software (Tree Star).
ARMS2 deposition CHO-K1, pgsD-677, pgsA-745
(each 1 × 106), native RPE (1 × 105), human erythrocytes
(each 1 × 107) as well as isolated naive T cells (1 × 106)
were incubated with increasing amounts of ARMS2 (10–
500 nM) in assay buffer (1% (w/v) BSA in PBS) for 1 h
on ice. ARMS2 binding was detected with rabbit ARMS2
antiserum (1:200) and an Alexa-647 conjugated antibody
(Life Technologies) (1:400). Similarly, factor H (10–
500 nM, Comptech) was bound to CHO-K1 cells.
Heparan sulfate competition assay Recombinant
ARMS2 (500 nM) was incubated with 1 × 107 heparin
coated beads (GE Healthcare) and increasing amounts of
heparan sulfate (0–12 mM, Sigma) in assay buffer (1% (w/
v) BSA in PBS) for 1 h on ice. ARMS2 binding was de-
tected with rabbit ARMS2 antiserum 1:200 and Alexa-647
conjugated antibodies (Life Technologies) 1:400. Factor H
(500 nM, Comptech) was incubated with the beads and
detected with factor H antiserum (Comptech).
C3b deposition Complement activation assays were
performed as previously described [19]. CHO-K1 and
pgsA-745 (each 1 × 106) were incubated in 20% NHS, or
heat-inactivated 20% NHS (hiNHS) (30 min at 56 °C)
forms healthy human donors in Mg2+EGTA buffer (1%
(w/v) BSA, 20 mM HEPES, 144 mM NaCl, 7 mM
MgCl2, 10 mM EGTA, pH 7.4) for 45 min at 37 °C. C3b
deposition was determined by flow cytometry using
mouse α-C3b monoclonal antibody (FitzGerald) diluted
1:100 and secondary Alexa-647 conjugated antibodies
(Life Technologies) diluted 1:200 in Mg2+EGTA buffer
for 1 h on ice. Deposition was normalized and NHS
alone defined as 100%. Influence of ARMS2, factor H
(CompTech), or HSA (Nutritional Biochemicals) on C3b
deposition was evaluated, after preincubation of either
cells (1 h on ice) or serum (15 min at 37 °C) with in-
creasing amounts of each protein (100 to 750 nM).
Properdin deposition CHO-K1 cells (1 × 106) were pre-
incubated with 500 nM ARMS2 for 1 h on ice. Washed
cells were incubated either in 20% NHS diluted with
Mg2+EGTA buffer (1% (w/v) BSA, 20 mM HEPES,
144 mM NaCl, 7 mM MgCl2, 10 mM EGTA, pH 7.4) or
EDTA buffer (1% (w/v) BSA, 20 mM HEPES, 144 mM
NaCl, 10 mM EDTA, pH 7.4) for 45 min at 37 °C or
with 100 nM purified properdin (CompTech) in PBS
containing 1% BSA for 1 h at RT. Properdin deposition
was analyzed by flow cytometry using a properdin
monoclonal antibody (QuiDel) (1:200) followed by an
Alexa-647 conjugated antibody (Life Technologies)
(1:400).
Statistical analysis
Significant differences between two groups were ana-
lyzed using the Student’s two-tailed t test. Values of
*p < 0.05, **p < 0.01, ***p < 0.001 were considered sta-
tistically significant.
Micklisch et al. Journal of Neuroinflammation  (2017) 14:4 Page 5 of 15
Results
Human monocytes and iPS-derived microglia cells express
ARMS2
A typical hallmark of AMD is the accumulation of cellu-
lar material in the form of drusen in the macular region
of the retina [1]. Normally, microglia cells, the resident
macrophages of the retina, take up modified or dead
cells by phagocytosis and the uptake of C3b opsonized
cellular debris is markedly enhanced [21, 22]. Since infil-
tration of inflammatory monocytes is reported in AMD
retinas [23], we first asked whether monocytes express
ARMS2 and determined ARMS2 mRNA expression in
these cells. A specific RT-PCR amplicon was generated
with cDNA derived from the human monocytic THP-1
cells and also from human primary monocytes (Fig. 1a).
DNA sequencing confirmed that this amplicon repre-
sented ARMS2 (data not shown), thus demonstrating ex-
pression of ARMS2 in human monocytes. Next, we
analyzed whether microglia cells, the resident immune
cells of the brain and the retina, [24] express ARMS2
transcripts. To circumvent the viability problems with
human postmortem microglia, ARMS2 transcription was
analyzed in microglia cells derived from human induced
pluripotent stem cells (iPSdM) [17]. Using the same
ARMS2 specific primers as before, a specific ARMS2
amplicon was generated with microglia-derived cDNA
(Fig. 1a). ARMS2 expression was previously shown in
the retina, placenta, and whole blood [2, 12, 25]. Here,
we additionally identified ARMS2 gene expression in hu-
man blood monocytes and microglia cells.
Expression of recombinant ARMS2 and generation of
antibodies
To detect the endogenous ARMS2 protein in mono-
cytes, a new polyclonal rabbit ARMS2 antiserum was
raised against a recombinant histidine-tagged ARMS2
protein expressed in P. pastoris. The polyclonal anti-
serum was characterized by the identification of the
main epitope in ARMS2 bound by the antibodies. There-
fore, 33 ARMS2 peptides each 13 amino acid long and
with an overlap of three amino acids were spotted to a
membrane and subsequently stained with the polyclonal
ARMS2 antiserum. The antibodies bound predominantly
to the C-terminal end of ARMS2 (Fig. 1b). When sepa-
rated by SDS-PAGE under reducing conditions, recom-
binant ARMS2 appeared with mobilities of 17 and
15 kDa by immune staining using the new antiserum
and also with a commercial ARMS2 antiserum or a His-
tag mAb (Fig. 1c). The 17 kDa protein band was cut out,
deglycosylated, digested by trypsin, and then analyzed by
mass spectrometry. All peptides derived from the
17 kDa band covered regions (95%) of ARMS2. MS of
the untagged, deglycosylated protein revealed a domin-
ant protein peak with a mass of 11.349 Da.
Monocytes derived from AMD patients with the ARMS2
risk haplotype lack the ARMS2 protein
The ARMS2 risk variant is defined by the polymorphism
rs10490924, which is linked to an indel mutation
(del443ins54) in the 3′ untranslated region of the
ARMS2 gene [12]. The ARMS2 indel mutation is consid-
ered to lead to ARMS2 mRNA instability, as this muta-
tion deletes the poly A signal and integrates two
AUUUA motifs that mediate rapid mRNA turnover. To
determine whether this ARMS2 risk variant (rs10490924
with del443ins54) affects ARMS2 expression, we deter-
mined ARMS2 expression on the protein level in periph-
eral blood monocytes isolated from genotyped AMD
patients. Monocytes of three different genotypes were
compared as follows: type I/I harbors two non-risk al-
leles of ARMS2. type I/II has one ARMS2 risk allele
(rs10490924 with del443ins54) and a non-risk allele, and
type III has two alleles of the ARMS2 risk variants
(rs10490924 with del443ins54). Blood monocytes of the
three genotypes were isolated from AMD patients, fixed
in chamber slides, permeabilized, and stained with
ARMS2 antiserum and with a monoclonal ARMS2 anti-
body. The ARMS2 protein was identified in the cyto-
plasm of monocytes harboring one or two alleles of the
ARMS2 non-risk variant (i.e., type I/I or I/II) (Fig. 1d).
In contrast, monocytes derived from the three patients
with two risk alleles (II/II) showed no ARMS2 protein
staining (Fig. 1c). Also, monocytes derived from a single
patient homozygous with an ARMS2 stop mutation
(rs2736911, genotype III/III) lacked the ARMS2 signal.
To verify ARMS2 presence in the monocytes, ARMS2
was also stained in monocytic cells THP-1 using poly-
clonal antiserum (αARMS2Jena). Again, single spots were
detected in the cytoplasm of the cells (Fig. 1d). In con-
trast, macrophages of murine origin lacked an ARMS2
signal. As the signal of ARMS2 in monocytes was very
weak, we tested whether ARMS2 expression is enhanced
under stress signals. Therefore, human blood monocytes
were challenged for 1 h with H2O2 and grown over night
and lysates investigated for ARMS2 expression by West-
ern blot analysis. Interestingly, ARMS2 expression in-
creased in monocytes upon oxidative stress (Fig. 1e).
Having shown that ARMS2 is expressed in THP-1 cells,
immunoprecipitation was performed combined with
mass spectrometry to detect the endogenous ARMS2
protein. A new generated monoclonal ARMS2 antibody
was bound to a protein G column, incubated with THP-
1 whole cell lysate, washed and antibody bound proteins
were eluted from the column. After separation via SDS
PAGE and coomassie blue staining, single bands were
extracted from the gel (Fig. 1f ). Mass spectrometry re-
vealed ARMS2 peptides in the cell lysate of THP-1 cells
(Fig. 1f ) and in probes derived from precipitated recom-
binant ARMS2 (not shown). Altogether, the results
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Fig. 1 ARMS2 expression in human monocytes and microglia cells. a Transcription of ARMS2 in uninduced or PMA (400 ng, 24 h) induced THP-1 monocytes,
mouse RAW 264.7 cells, microglial cells stimulated with LPS (5 ng/ml, 24 h) or blood-derived human monocytes. b New polyclonal antiserum generated to
recombinant ARMS2 detects the C-terminal part of ARMS2 as indicated by the dark spots. Peptides of ARMS2 (33 amino acids with an overlap of 3 amino
acids) were spotted to a membrane and incubated with the ARMS2 antiserum. c Recombinant ARMS2 expressed in P. pastoris and purified by
Ni2+ chromatography appears as monomeric protein of about ~15/17 kDa identified by silver staining or Western blot analysis using either monoclonal
penta-Histidin, purchased polyclonal ARMS2 antiserum (αARMS2Com) or polyclonal ARMS2 antiserum (αARMS2Jena), generated to the recombinant protein)
as indicated. The ARMS2 protein without purification tag showed a mobility of about 11 kDa. Mass spectrometry of the deglycosylated 17 kDa ARMS2 band
revealed ARMS2 peptides (raw data). MS of the whole protein showed a protein with a mass of 11.349 kDa. d ARMS2 is present in monocytes
with one or two copies of the non-risk ARMS2 variant, but is absent in cells with the homozygous rs10490924 (II/II) or rs2736911 (III/III) polymorphism. ARMS2
is detected in the cytoplasm of THP-1 cells (I/II), but ARMS2 is absent in RAW264.7. cells. Cells in (d) were permeabilized, stained for ARMS2 (red) or DNA (blue)
and visualized by laser scanning microscopy. Scale bar = 10 μm. e Blood-derived monocytes express ARMS2 upon oxidative stress. Cells were incubated
for 1 h in medium with H2O2 (0.001–1 mM), for another 20 h in normal medium, lysed in loading buffer, and proteins were separated by SDSPAGE and
immunoblotted using αARMS2Jena. Densitometric analysis is shown in the graph below. The same blot was also stained for β-actin as a loading control.
f Immunoprecipitation of ARMS2 from THP-1 cell lysate (1 × 107) with new monoclonal ARMS2 antibodies. Eluted proteins were separated by SDS-PAGE,
stained with coomassie blue and single bands (white bars) investigated by mass spectrometry. ARMS2 peptides from five immunoprecipitations are shown.
Precipitation of recombinant ARMS2 revealed ARMS2 petptides (data not shown). Experiments shown in a to e are representatives of three independent
experiments. Δm/z [ppm] mass tolerance, ARMS2-IP imunoprecipitation of recombinant ARMS2, THP1-IP ARMS2 immunoprecipitated from THP-1 cells
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demonstrate for the first time ARMS2 protein expres-
sion in monocytes and that the risk variants of ARMS2
lead to ARMS2 deficiency in these cells.
We next analyzed ARMS2 expression and localization in
retinal tissue and tried to identify the responsible cells in
the human retina, which express the protein. To this end,
retinal tissue cross sections from genotyped individuals
were analyzed by histology using the new ARMS2
antiserum. ARMS2 was identified in stained cross sections
of the retina derived from individuals with the I/I genotype
(Fig. 2A, B I–IV), but ARMS2 was not detectable in sec-
tions of the II/II genotype (one representative of three
stainings is shown, Fig. 2B IX, X). ARMS2 immunoreactiv-
ity appeared in the inner retinal layer as a speckled pattern
and was also seen in the choroid (Fig. 2A, B V–VIII), which
is in agreement with the presence of ARMS2 in monocytes.
Fig. 2 ARMS2 expression by retinal microglia cells. A I, II Co-labeling of ARMS2 (green) and the macrophage/microglia marker CD68 (red) in the human
retina shows co-localization (white arrowheads) of ARMS2 and CD68 indicating ARMS2 expression by retinal microglia cells/macrophages in the human
retina. Note that blood monocytes in retinal vessels (dotted lines) co-labeled for ARMS2 and CD68. A II, IV Co-labeling of ARMS2 and CD68 shows that
retinal microglia are associated with cells of the inner retina that contain high amounts of ARMS2 on their cell surfaces (white squares). A IV–XII Magnifications
of squared areas in (II and IV) show close association of microglia with retinal neurons and strong ARMS2 immunoreactivity (white arrowheads). Left panels
(V–VIII) show ARMS2 and CD68. Right panels (A IX–XII) show merged pictures of ARMS2 and CD68 and DAPI. INL inner nuclear layer, IPL inner
plexiform layer, GCL ganglion cell layer. Scale bar (A I–IV) 50 μm; scale bar (A V–XII) 25 μm. B I, II ARMS2 staining of retinal cross section
through the fovea of a human donor with haplotype (I/I). The white squares indicate the area of the macular that is magnified in (B II, IV). B V, VI ARMS2
immunoreactivity in retinal cross section of parafoveal areas obtained from a human donor with haplotype (I/I). The white squares indicate the area of RPE
and choroid magnified in (B VII,VIII). ARMS2 staining in the choroid is presumably confined to monocytes and choroidal macrophages, in the retina to
microglia cells (arrows) (B IX, X). Retinal cross section from a human donor with haplotype (II/II) that is devoid of ARMS2 immunoreactivity also in the
choroid. B XI, XII Control stainings lacking primary antibody. Green autofluorescence lining at the top of the images is derived from RPE (asterisk). Scale bar
(B I, II, V, VI, IX, X) 50 μm; scale bar (B III, IV, VII, VII, XI, XII) 25 μm
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As iPS-derived microglia cells express the ARMS2 gene
(Fig. 1a), we aimed to demonstrate ARMS2 expression also
for the resident retinal microglia. The surface marker CD68
identified several microglia cells in the cross-section that
were ARMS2 positive (Fig. 2A I–IV). The CD68 positive
ARMS2 expressing microglia cells were frequently associ-
ated with neurons that were highly decorated with ARMS2
(Fig. 2AV–VII). Thus, retinal microglia cells with the geno-
type I/I very likely express and secrete ARMS2, which then
binds to neurons.
ARMS2 binds to cell surfaces
To further define the role of the ARMS2 protein, we
followed up on the observation of ARMS2 deposited on
neurons of the retina and investigated whether ARMS2
binds to cell surfaces using flow cytometry. Purified re-
combinant ARMS2 did not bind to RPE cells (Fig. 3a) or
to human erythrocytes (Fig. 3b). To test if ARMS2 binds
specifically to modified human surfaces, we measured
ARMS2 binding to naïve, apoptotic, or necrotic human
T cells. Apoptotic or necrotic T cells were identified as
annexin V and PI positive cells by flow cytometry. In this
set up, ARMS2 bound to late apoptotic and necrotic T
cells but did not bind to naïve or to early apoptotic T cells
(Fig. 3b). This surface attachment is in agreement with the
reported ARMS2 binding to extracellular matrix proteins
[2, 26] and the localization of ARMS2 close to the drusen,
which represent accumulated cellular debris as shown by
proteome analysis and immune staining [26, 27].
ARMS2 binds to heparan sulfate
To identify cellular ARMS2 ligands, we studied whether
ARMS2 cell surface binding is mediated by surface ex-
posed glycosaminoglycans (GAGs). To this end, we ana-
lyzed ARMS2 binding to CHO-K1 (Chinese Hamster
Ovary) cells, which expose sulfated GAGs and also to
two mutant lines, which lack surface heparan sulfates.
ARMS2 bound to wild type CHO-K1 cells but did not
bind to the mutant CHOpgsA or to CHOpgsD cells
(Fig. 3d). GAGs represent complex polysaccharides and
are exposed at the surface of mammalian cells; GAGs
sulfation provides a recognition signal for proteins [28]. To
confirm ARMS2 interaction with heparan sulfate in the
absence of other cell surface ligands, we studied ARMS2
Fig. 3 ARMS2 binding to cell surfaces. a Binding of ARMS2 (500 nM, 1 h) to naive RPE-cells and (b) human erythrocytes. c ARMS2 binding to
untreated (n = 3), early apoptotic (n = 4), late apoptotic (n = 3), and necrotic (n = 4) T cells. T cells were gated according to their staining with
annexin V-pacific blue and PI (upper panels), flow cytometry of indicated gates are shown (lower panels). ARMS2 bound in a dose-dependent manner
(***p = 0.0001 for necrotic and ***p = 0.0002 for late apoptotic cells, each 10 nM versus 500 nM ARMS2). Background binding of the antibody to the
cells is marked (co). d ARMS2 binding for 1 h to CHO-K1 (n = 4), CHOpgsA, or CHOpgsD cells (each n = 5). Flow cytometry experiments show the median
MFI values ± s.d. using ARMS2 antiserum (***p = 0.0001, 10 nM versus 500 nM ARMS2). e ARMS2 binding to heparin coated beads (n = 3,
median MFI values ± s.d., ***p= 0.0002) and in competition with free heparan sulfate (4–12 mM, n= 3, ***p= 0.0002, 0 mM versus 12 mM heparan sulfate,
and **p= 0.016, 4 mM versus 12 mM heparan sulfate). Competition is shown in percent of binding of ARMS2 to the beads alone (100%)
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binding to heparin-coated beads. ARMS2 bound to
the coated beads, and binding was blocked when ARMS2
was incubated with heparan sulfate prior to binding
(Fig. 3e). Thus, ARMS2 binds to cell surfaces via GAGs.
Cell surface bound ARMS2 enhances complement activation
Complement is involved in the pathogenesis of AMD as
revealed by genetic association studies and also by the
presence of complement products in drusen [1, 9, 10, 27].
Given the key role of deregulated complement in AMD
pathophysiology, we postulated that ARMS2 influences
complement activation. To test this hypothesis, ARMS2
was added to normal human serum (NHS) and this mix-
ture was then added to CHO-K1 cells. Following incuba-
tion and washing, surface C3b deposition was determined
by flow cytometry. Addition of NHS to CHO-K1 cells
induced complement activation, which was set as 100%.
However, ARMS2, when added to NHS, enhanced C3b
opsonization of CHO-K1 cells and this effect was dose-
dependent (Fig. 4a). In contrast, no enhanced C3b
Fig. 4 ARMS2 functions as complement activator on the cell surface. a C3b deposition on CHO-K1 cells is enhanced after incubation for 45 min
in 20% NHS preincubated with ARMS2 (100–750 nM) (n = 4, **p = 0.0021, 100 nM versus 750 nM). Human serum albumin (HSA) had no and factor
H an inhibiting effect on C3b deposition. C3b deposition on cells in NHS alone was set as 100%. b C3b deposition on CHOpgsA cells is not enhanced
after incubation in 20% NHS with ARMS2, factor H or HSA (each 100–750 nM) (each n = 3). C3b deposition on cells in NHS alone was set as
100%. c Deposition of C3b is increased on ARMS2 (100–750 nM) coated CHO-K1 cells (n= 4, **p= 0.0021) after incubation in 20% NHS. HSA or factor H
does not enhance C3b binding. d ARMS2 (500 nM) attached to CHO-K1 cells and incubated for 45 min in 20% NHS enhanced C3b deposition over time
as compared to cells alone in 20% NHS (latter was set as 100%). Error bars show median MFI values ± s.d. (n= 3, **p= 0.0011, NHS versus NHS + ARMS2). e
ARMS2 (100–750 nM) added to 20% NHS without cells did not enhance Ba generation, as determined by ELISA. Data represent mean values
± s.d. (n = 3). f Deposition of C3b on ARMS2 (100–750 nM) coated CHO-K1 cells is enhanced in 20% complement active NHS incubated for 45 min but
not in heat inactived NHS (30 min, 56 °C). Data represent median MFI values ± s.d. in % (NHS alone was set as 100%) (n = 3, **p = 0.0014, NHS versus
hiHS at 750 nM ARMS2)
Micklisch et al. Journal of Neuroinflammation  (2017) 14:4 Page 10 of 15
depositon was observed for the mutant line CHOpgsA cells
that do not bind ARMS2 (Fig. 4b). C3b opsonization was
even more pronounced when ARMS2 was attached to the
surface of CHO-K1 cells prior to addition of NHS (Fig. 4c),
and complement activation was followed over a time period
of 45 min. ARMS2 coated to CHO-K1 cells increased C3b
deposition by threefold (Fig. 4d) as compared to cells
coated with HSA. This increase of C3b surface decoration
suggested that ARMS2 attached to a cell surface activates
the amplification loop of complement. In contrast to
ARMS2, factor H blocked complement activation in this
setup. Remarkably, ARMS2, when added to NHS as a fluid
phase protein, did not affect complement activation and in
this case, no complement cleavage products like Ba were
generated (Fig. 4e). As expected, factor H, when added to
NHS in fluid phase, reduced Ba levels. ARMS2 on the sur-
face of CHO-K1 and then incubated with heat-inactivated
serum (hiHS) did not affect C3b deposition (Fig. 4f). Thus,
ARMS2 is a complement activator that acts exclusively on
surfaces.
ARMS2 binds the human complement activator properdin
To determine how ARMS2 activates complement, binding
of ARMS2 to the components of the C3 convertase and to
C3 activation products was evaluated. ARMS2 did not bind
to C3, to factor B, or to the cleavage products C3b, iC3b,
and C3d (Fig. 5a). However, ARMS2 bound to properdin,
the only known complement activator [29, 30, 31]. ARMS2
binding to properdin was dose-dependent (Fig. 5b).
To clarify whether ARMS2-properdin complexes recruit
C3b, binding of C3b to preformed ARMS2-properdin
complexes was followed. ARMS2 was immobilized to a
microtiter plate, properdin was attached, and subse-
quently, C3b was added. Purified C3b bound to the immo-
bilized ARMS2-properdin complex as determined by
ELISA, and binding was dose-dependent (Fig. 5c). Thus,
surface-bound ARMS2 binds properdin and subsequently,
ARMS2-properdin complexes recruit C3b. These results
are in agreement with enhanced C3b opsonization when
ARMS2 was coated onto CHO-K1 cells prior to challenge
with complement active NHS (Fig. 4a). The ARMS2-
properdin interaction was confirmed by biolayer interfer-
ometry. Recombinant ARMS2 was immobilized to a Ni2+
NTA biosensor, and purified properdin was added as ana-
lyte. In this set up, properdin bound to immobilized
ARMS2 with a kD = 0.5 ± 0.07 × 10
−6 M (Fig. 5d). In order
to localize the domain in ARMS2, that interacts with pro-
perdin, three ARMS2 peptides encompassing all amino
acids of ARMS2 were coated to a microtiter plate and in-
cubated with properdin. Peptide 3 of ARMS2, but not
peptides 1 or 2, showed binding to properdin (Fig. 5e).
These results confirm interaction of ARMS2 with proper-
din and localize the interaction domain in the C-terminal
part of ARMS2.
In NHS, properdin exists as trimers or tetramer com-
plexes, and larger complexes are considered artifacts
[30]. Therefore, binding of native serum-derived as well
as neutrophil-derived properdin was evaluated to
ARMS2 coated cells. CHO-K1 cells to which ARMS2
was attached were incubated in complement active NHS
or in culture supernatant derived from human neutro-
phils. Following washing of the cells, ARMS2 and pro-
perdin were identified by confocal microscopy (Figs. 5b
and 6a). ARMS2 and properdin, either derived from
NHS or from supernatant of neutrophils, co-localized on
the surface of CHO-K1 cells. Properdin binding to cell
surfaces is often C3b dependent [32]. To demonstrate that
ARMS2 recruits properdin directly and that ARMS2-
properdin complexes form in the absence of C3b, binding
of properdin, derived from complement active and in-
active NHS, to ARMS2 coated CHO-K1 cells was followed
by flow cytometry (Fig. 6c). ARMS2 coated to the cells
bound purified properdin. ARMS2 also bound properdin
from NHS treated with EGTA, which chelates Ca2+ and
inhibits the classical complement pathway but leaves the
alternative pathway intact. Also, when EDTA that inhibits
Mg2+ and Ca2+ dependent C3 convertase formation was
added to NHS to block C3b generation, properdin bound
to surface attached ARMS2. Only when properdin de-
pleted serum was used no properdin, binding to ARMS2
coated CHO-K1 cells was detected (Fig. 6d). Thus
ARMS2-properdin complexes are also formed in the ab-
sence of C3b. Altogether, the data show that ARMS2 is a
surface acting molecule that enhances C3b opsonization
via binding of properdin. Thus, microglia cells with the
non-risk ARMS2 gene can enhance opsonization and
phagocytosis of dead cells by the generation and secretion
of ARMS2.
Discussion
The present study demonstrates expression of ARMS2 in
human monocytes as well as in human microglia cells.
The ARMS2 expresssion was upregulated in monocytes
upon oxidative stress. Deficiency of the ARMS2 protein
was observed in monocytes homozygous of the AMD as-
sociated genetic polymorphism rs10490924 in the ARMS2
gene. In addition, recombinant ARMS2 binds to surfaces
of dead cells and when attached to cellular surfaces,
ARMS2 anchors the complement activator properdin. By
recruiting and anchoring properdin to cellular surfaces,
ARMS2 enhances local complement activation and C3b
surface opsonization. C3b/iC3b “tagging” of cells likely fa-
cilitates phagocytosis and ultimately removal of cellular
debris (Fig. 7). This role of ARMS2 underlines the pivotal
role innate immunity plays in retinal homeostasis.
ARMS2 mRNA is expressed in human monocytes and
also in stem cell induced human microglia cells, but not
in murine macrophages. Expression in human but not in
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murine cells is in agreement with the relatively late evolu-
tionary appearance of the ARMS2 gene in humans and
higher primates [15]. Using a new antiserum, which was
generated by immunizing rabbits with recombinant
ARMS2 proteins, endogenous ARMS2 protein expression
was detected in monocytes derived from individuals with
the wild type ARMS2 genotype and also in the human
monocytic cell line THP-1, which is heterozygous for the
risk ARMS2 haplotype. Similarly, ARMS2 was immuno-
precipitated from THP-1 cells with a novel monoclonal
ARMS2 antibody. However, the ARMS2 concentration
was very low indicating that a trigger is necessary for
ARMS2 expression in the cells. Indeed, after blood mono-
cytes were stressed with H2O2, ARMS2 expression was
induced and detected also by Western blotting. Thus,
ARMS2 is expressed upon oxidative stress in monocytes
and likely also microglia cells, which is in agreement with
oxidation specific epitopes on damaged cells in the retina
which induce complement activation (3). The recombin-
ant ARMS2 protein, when separated under reducing con-
ditions, appeared as a band with a molecular mass of
about 17 kDa, which was identified as ARMS2 by mass
spectrometry. The whole deglycosylated, untagged recom-
binant protein showed a mass of 11.349 kDa, which is
smaller than the calculated mass of 11.4 kDa. The differ-
ence is explained by pre-treatment of the protein (degly-
cosylation and removal of the histidine tag). However,
deglycosylation of recombinant ARMS2 did not alter
binding of ARMS2 to cells or interaction with proteins
(data not shown).
ARMS2 gene variations represented by two different
polymorphisms, affect ARMS2 protein expression in
monocytes. The risk variant represented by polymor-
phisms rs10490924 is linked with the indel mutation,
which affects mRNA stability [12]. The second poly-
morphism, i.e., rs2736911, which is very rare in homozy-
gous setting in Caucasians but more frequent in
individuals of Chinese origin [33], generates a premature
stop codon at position 38. Apparently, both polymor-
phisms rs10490924 and rs2736911 result in ARMS2 pro-
tein deficiency as shown in monocytes and retinal
section stainings. These results confirm the recent re-
ports demonstrating that the indel mutation in the 3′
untranslated region of the ARMS2 gene leads to RNA
Fig. 5 ARMS2 interacts with properdin. a Binding of ARMS2 (500 ng, 1 h) to immobilized C3 convertase components properdin, C3, C3b, iC3b, C3c, C3d,
and factor B (each 500 ng). Error bars represent mean ± s.d. (n= 4, ***p= 0.0001, properdin versus buffer). A stippled lane indicates background binding. b
Properdin (12.5–100 nM) binding to immobilized ARMS2 or HSA. Error bars represent mean ± s.d. (n= 3, **p= 0.001, 12.5 nM versus 100 nM properdin). c
C3b (4–32 nM, 1 h) binding to properdin (100 nM) attached to immobilized ARMS2 is increased but not to immobilized ARMS2 alone. (n = 3,
***p= 0.001, 4 nM versus 32 nM C3b). d Affinity constant of the interaction between ARMS2 and properdin was determined by biolayer interferometry.
Recombinant ARMS2 was immobilized to the biosensor, and interaction of properdin was determined (mean value ± s.d. of two independent
experiments). e Recombinant ARMS2 binds properdin within the C-teminal domain. Properdin binding was evaluated to three peptides of
ARMS2 immobilized to the plate. Amino acid sequences of the peptides are indicated
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instability [12, 25] and ARMS2 protein deficiency in pla-
centa tissue, derived from a person with the ARMS2 risk
genotype [12]. These data may help to resolve the
contradictory views that exist over ARMS2 as a key ef-
fector protein in AMD and on the functional conse-
quences of the polymorphism rs10490924 in ARMS2
[34]. The polymorphism rs10490924 is in strong linkage
disequilibrium with SNP rs1100638 in the HTRA1 (high
temperature requirement factor A1) gene [12, 34, 35]
which makes effects by these polymorphisms indistin-
guishable in statistical analyses.
The innate immune system constantly monitors a
spectrum of surfaces, including self, altered self and
non-self. Potential targets are recognized on the basis of
their characteristic surface molecular patterns. We here
demonstrate that the recombinant ARMS2 protein like
the complement regulator factor H binds preferentially
to apoptotic and necrotic surfaces and identifies heparan
sulfate as an ARMS2 ligand. Interestingly, surface-bound
recombinant ARMS2, but not in fluid phase, serves as
an anchor for the human complement activator proper-
din. ARMS2-properdin complexes formed at cellular
surfaces enhanced C3 convertase formation and C3 con-
vertases mediated C3b opsonization. Such marking of
surfaces with C3 cleavage products accelerates recogni-
tion, uptake and clearance of debris by human phago-
cytes [21, 22], and binding of properdin to apoptotic
cells enhances this process [28]. Notably, in addition to
surface complement activation, complement regulators
like factor H and C4bp are recruited to the surfaces to
restrict the complement cascade and to inhibit inflam-
mation and autoimmune reactions [3, 21, 22].
Conclusions
The data presented suggest that ARMS2 assists in the clear-
ance of cellular debris in the human retina. Recombinant
Fig. 6 ARMS2 anchors the human complement activator properdin on cell surfaces. a Co-localization (yellow) of ARMS2 (green) and purified properdin
from NHS (red) or (b) properdin from supernatant of human neutrophils (red) on CHO-K1 cells by laser scanning microscopy. Nuclei are stained
with DAPI (blue). Scale bar 5 μm. Representative data from two independent experiments are shown. c Recruitment of purified (left profile) and endogenous
properdin to ARMS2 on CHO-K1 cells. ARMS2 was attached to CHO-K1 cells and incubated for 1 h with purified properdin or in alternative pathway active
(Mg2+ EGTA), complement inactive (EDTA), or properdin deficient HS as indicated. Properdin binding was determined by flow cytometry. Representative
binding profiles of two independent experiments are shown. Background binding of the antibody to the cells is marked (co)
Fig. 7 Schematic overview of ARMS2 functions. Human monocytes or
microglia cells express ARMS2, which is likely secreted by a non-classical
pathway and which attaches to late apoptotic and necrotic cells,
recruits properdin and enhances C3b opsonization by complement
activation. Opsonization of particles with C3b augments phagocytosis.
AMD patients homozygous for the ARMS2 risk haplotype (II/II) show
ARMS2 protein deficiency in their monocytes
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ARMS2 distinguishes certain modified cells via surface
glycosaminoglycan structures and initiates complement.
Therefore, in case of ARMS2 deficiency complement-
mediated opsonization, uptake and phagocytosis of dying
cells are expected to be impaired. Over a long time, i.e.,
over years, such a reduced clearance may support accu-
mulation of cellular debris in the retinal space and along
Bruch’s membrane enhancing formation of drusen, the
hallmark of AMD.
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